Hurricanes Do More Damage than What’s on the Surface

Hurricanes Do More Damage than What’s on the Surface

In the wake of hurricane season, many people only think about the physical path of destruction these natural disasters leave behind. From property damage to death, hurricanes have a lasting impact. Hurricane Dorian became a monstrous category 5 that devastated the Bahamas. The death toll as of September 10th totaled fifty, and it’s still climbing. Parts of Grand Abaco still are not fully accessible, except by helicopter. Over 60% of homes were completely destroyed, leaving thousands homeless.

Aside from physical aftermath of a hurricane, many economic impacts exist as well. The Congressional Budget Office estimates that government costs for hurricane damage is near $30 billion per year and gradually increases each year. Whatever government agencies do not pay out for damage, the remainder is covered by state and local governments, insurance companies, and the individuals affected. This article features some of the commonly overlooked economic disruptions resulting from a hurricane.

Local Business Disruption. Local businesses typically shut down prior to the storm and days to weeks following the impact, depending on how severe. Closing doors means days where sales and production are low to none. Many small companies that shut down cannot reopen for extended periods of time due to unexpected damages. If the damage is far beyond repair, such as the damage done by Hurricane Dorian, these small businesses are not able to open their doors again. Among these are typically restaurants and other small service businesses.

Commodity Prices. Natural disasters, especially hurricanes, can have a huge impact on commodity prices. A perfect example of this is Hurricane Katrina’s destruction to the refineries in the Gulf.  More than 50% of the gasoline consumed by the U.S. passes through those refineries. Consequently, gas prices rose, and the transportation sector saw shrinking margins as they had to increase their rates.

Financial Services. Regarding investments, companies such as insurance have to pay out millions to their insured clients following a hurricane. The large payouts take a toll on their earnings, which is then reflected in the stock price. Many small companies are not prepared to take on these payouts all at once. Portfolios or ETFs with companies that are directly affected may not see positive returns for many quarters.

Property Value. When hurricanes sweep through certain areas and leave long-term damage, the property value of the homes decline. An expensive neighborhood a couple of miles away from an area that was leveled by a hurricane will see a decline in the property value because the surrounding area is no longer up to value. Other factors that can negatively impact property value are the number of business that had to close or schools that are no longer functional.

With our highly integrated economy, almost every sector will see a direct or indirect impact from a hurricane. Besides the infrastructure damage, many people may not see the economic consequences beyond that. From largecap companies to smallcap local business and restaurants, almost everyone can feel the impact. Commodity prices are affected, financial service groups have to payout millions, and the property value of homes in these areas often decline. So when it comes to preparing for a hurricane, besides the bottled water and extra snacks, remember to take a look at your portfolios and surroundings to properly prepare for the worst possible scenario.

 

 

Sources:

https://www.npr.org/2019/09/05/757858192/in-bahamas-officials-assess-generational-devastation-from-hurricane-dorian, Brakkton Booker September 5, 2019

https://www.thebalance.com/hurricane-damage-economic-costs-4150369, Kimberly Amadeo June 25, 2019

https://www.investopedia.com/financial-edge/0311/the-financial-effects-of-a-natural-disaster.aspx, Mary Hall August 30, 2019

Independent Researchers Find Genprex’s TUSC2 Prevents Tumor Growth in Triple-Negative Breast Cancer

Independent Researchers Find Genprex’s TUSC2 Prevents Tumor Growth in Triple-Negative Breast Cancer

AUSTIN, Texas & CAMBRIDGE, Mass.

Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company, announced that independent researchers reported in a recent study that TUSC2, a tumor suppressor gene and the active agent in Genprex’s Oncoprex™ immunogene therapy, prevented tumor growth in triple-negative breast cancer (TNBC), which is currently considered an incurable cancer with limited therapeutic options. Genprex has no affiliation with these researchers.

The study, published in Nature, first found MicroRNA-138 as a diagnostic biomarker for TNBC, which currently lacks targeted therapies due to its inability to express the estrogen and progesterone hormone receptors and the human epidermal growth factor receptor 2 (HER2), thus the name for triple-negative breast cancer. Depletion of miR-138 was found to lead to apoptotic cell death in vitro and prevented tumorigenesis in vivo. TUSC2 was found to be a direct target of miR-138, and TUSC2 mimics the effects of miR-138 knockdown, preventing tumor growth. The researchers deduced that TUSC2 is a downstream tumor suppressor that is directly repressed by miR-138.

The study reports that triple-negative breast cancer is an extremely aggressive subtype of breast cancer which is associated with poor prognosis and high mortality rates. The lack of targeted treatment for triple-negative breast cancer makes it an increasingly feared diagnosis.

Genprex is conducting clinical and pre-clinical research to evaluate the effectiveness of TUSC2 when combined with targeted therapies and immunotherapies for non-small cell lung cancer. Existing pre-clinical data also suggest that TUSC2 may be effective against glioblastoma, head and neck cancer, kidney cancer, and soft tissue sarcomas. Now, this new independent study raises the possibility that TUSC2 expression, through miR-138 targeting, may also be used to treat the most aggressive subset of breast cancer.

“The results of the study evaluating TUSC2 for the treatment of triple-negative breast cancer are encouraging,” said Rodney Varner, Genprex’s Chairman and Chief Executive Officer. “We believe that the data reported in this Nature article by independent researchers supports our belief that TUSC2 may be effective to treat a variety of cancers, including some of the most deadly types of cancer.”

About Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, please visit the company’s web site at www.genprex.com or follow Genprex on TwitterFacebook and LinkedIn.

Forward-Looking
Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of TUSC2 on cancer, our current and planned clinical trials, and the commercialization of our product candidates. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of TUSC2’s effect on cancer, the timing and success of our clinical trials and planned clinical trials of TUSC2 and Oncoprex™ and our other potential product candidates and the timing and success of obtaining FDA approval of Oncoprex™ and our other potential product candidates. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

View source version on businesswire.com: 
https://www.businesswire.com/news/home/20190911005097/en/

Genprex, Inc. 
(877) 774-GNPX (4679)

Investor
Relations 

GNPX Investor Relations 
(877) 774-GNPX (4679) ext. #2 
[email protected]

Media Contact 
Genprex Media Relations 
Kalyn Dabbs 
(877) 774-GNPX (4679) ext. #3 
[email protected]

Copyright Business Wire 2019

News Provided by Business Wire via QuoteMedia

Eagle Bulk Shipping Inc. Takes Delivery of M/V Dublin Eagle

Eagle Bulk Shipping Inc. Takes Delivery of M/V Dublin Eagle

STAMFORD, Conn.,, Sept. 11, 2019 (GLOBE NEWSWIRE) — Eagle Bulk Shipping Inc. (NASDAQ: EGLE) (“Eagle Bulk” or the “Company”), one of the world’s largest owner-operators within the Supramax / Ultramax segment, today announced that it has taken delivery of the first of six modern Ultramax drybulk vessels the Company has previously agreed to acquire.

The ship, which has been renamed the M/V Dublin Eagle, is a 2015-built, high specification scrubber-fitted SDARI-64 Ultramax vessel built at Jiangsu New Hantong Ship Heavy Industry Co., Ltd.

Proforma for the five remaining acquisition vessels, which have yet to be delivered, the Company’s fleet will total 50 ships, including 20 Ultramax drybulk vessels acquired over the last 36 months.

About Eagle Bulk Shipping Inc.

Eagle Bulk Shipping Inc. (“Eagle” or the “Company”) is a US-based fully integrated shipowner-operator providing global transportation solutions to a diverse group of customers including miners, producers, traders, and end users. Headquartered in Stamford, Connecticut, with offices in Singapore and Copenhagen, Eagle focuses exclusively on the versatile mid-size drybulk vessel segment and owns one of the largest fleets of Supramax/Ultramax vessels in the world. The Company performs all management services in-house (including: strategic, commercial, operational, technical, and administrative) and employs an active management approach to fleet trading with the objective of optimizing revenue performance and maximizing earnings on a risk-managed basis. For further information, please visit our website: www.eagleships.com.

Company Contact:
Frank De Costanzo
Chief Financial Officer
Eagle Bulk Shipping, Inc.
Tel. +1 203-276-8100

Media Contact:
Rose & Company
Tel. +1 212-359-2228

Research – Eagle Bulk Shipping (EGLE) – Signaling a Recovery

Tuesday, September 10, 2019

Eagle Bulk Shipping (EGLE)

Several Signs of Recovery Ahead

Eagle Bulk Shipping (EGLE) moves both major and minor dry bulk around the world. Adjusting for announced transactions, EGLE operates a fleet of 50 dry bulk vessels and transports bulk commodities, including coal, grain, iron ore, steel, cement, forest products, and other raw and finished materials. The current fleet consists of 16 Ultramax and 29 Supramax class dry bulk vessels, or mid-sized assets. After the latest acquisition of six Ultramaxes and the sale of one Supramax close in 3Q2019, there will be 20 Ultramaxes and 30 Supramaxes in the fleet. Ultramaxes are larger versions of Supramaxes and carry about 63k deadweight tons (DWT) and Supramaxes carry between 50k and 59k dwt.

Poe Fratt, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to full report for price target, fundamental analysis and rating.

  • Dry bulk market has firmed in 3Q2019 despite trade tension overhang.  There were clearly near-term challenges to the dry bulk market earlier this year due to trade tensions and slower global economic growth. However, dry bulk indices have improved in the past quarter and are currently near multi-year highs.
  • Acquisition update. Fleet expands and age profile improves.   The acquisition of six high-spec. SDARI-64 Ultramaxes in two transactions for ~$122 million is…



    Get full report on Channelchek desktop.


Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst
certification and important disclosures included in full report. 
NOTE: investment decisions should not be based upon the content of
this research summary.  Proper due diligence is required before
making any investment decision.
 

How Can Innovations in Transportation and Logistics Provide Value to Investors?

How Can Innovations in Transportation and Logistics Provide Value to Investors?

The transportation and logistics industry covers a broad range of sectors, such as shipping, freight, railroad, and truck transport, so investing in it provides opportunity for a diversified portfolio. Private, public, and governmental investing all help supply the necessary funding for the industry and improve the supply chain. Investment in new and public transportation systems, such as highways, streets, and airports, can provide value to both the investor and the community.

Cyclical Economic Shifts: Industrial Companies Could Feel the Effects

Cyclical Economic Shifts: Industrial Companies Could Feel the Effects

The Industrial sector provides numerous products and services that support many industries and companies. Industrial companies manufacture construction machinery and equipment, aircraft, and provide commercial and transportation services. Investing in industrial companies allows for diversified portfolios and long-term growth with a multi-trillion-dollar market cap. Many industrial companies are cyclical, so they are affected by economic shifts.

Will the Longest Economic Expansion in History Continue?

Will the Longest Economic Expansion in History Continue?

Job growth in the United States slowed more than expected in August. The U.S. labor market has been a key positive player amid weakening global economic data, but the most recent report is shaky. The Federal Reserve is expected to cut interest rates again this month to keep the expansion on track. 

Can Investing in Natural Resources Provide Future Value?

Can Investing in Natural Resources Provide Future Value?

Investing in natural resources can provide value as demand for resources such as lumber, precious metals, coal, and water will always exist. Natural resources are core to production, comprising many processed goods. Natural resource companies that either process or supply these resources will be in constant demand as the world population grows and expands. Investing in natural resources requires an understanding of a broad range of processes and extraction companies. Natural resources can be collected in a variety of forms and further processed, packaged, and sold by companies.

Will Renewable Energy be the Downfall of Fossil Fuels?

Will Renewable Energy be the Downfall of Fossil Fuels?

Fossil fuel has been the main energy source since the mid-1700s during the Industrial Revolution. It has provided the majority of our power since then, but research shows that when burned, it has negative impacts on the environment. For this reason, many countries have been searching for an alternative, preferably a renewable one. Solar and wind power have been the most prominent choices and have seen a jump in popularity in recent years.

Are the Trade Troubles Coming to an End?

Are the Trade Troubles Coming to an End?

For the past two years, President Donald Trump has been battling China in an attempt to create a mutually beneficial trade relationship. The two sides have continued to create significant disagreements in this drawn-out dispute, which has caused issues for both economies. Yet the markets have surprisingly bounced back each time. The increase has spiked investors’ confidence, but they are still waiting on a final deal.

Prescription Drug Pricing: How Would Limited Government Intervention Change the Landscape?

Prescription Drug Pricing: How Would Limited Government Intervention Change the Landscape?

Bringing down prescription drug prices has been a campaign promise by many presidents over the years. Making a deal with the pharmaceutical companies is not an easy task, as these companies operate just like any other, with a goal to maximize profit. Big Pharma companies produce drugs that save people’s lives, which comes with a price many who need it cannot afford, even with health insurance. Government deregulation could open the doors for other generic brands to enter the market and potentially drive down the costs of high-demand drugs. Smallcap companies in the sector would then be exposed to fair competition, rather than not standing a chance at all against pharmaceutical giants.

Dyadic to Present at Janney Healthcare Conference

Dyadic to Present at Janney Healthcare Conference

JUPITER, FL / ACCESSWIRE / September 4, 2019 / Dyadic International, Inc. (the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving and applying its proprietary C1 gene expression platform to speed up the development, lower production costs and improve the performance of biologic vaccines, drugs, and other biologic products, at flexible commercial scales, today announced that its President and Chief Executive Officer, Mark Emalfarb will be presenting at Janney Healthcare Conference:

Date: Monday, September 9, 2019
Presentation Time: 9:55 a.m. ET
Webcast Dial-In: U.S. & Canada Toll-Free 888-223-4954
Webcast Web Login: https://cc.callinfo.com/registration/#/?meeting=16eiy2ys5xd7m&campaign=1kvxafep0di9o
Location: The Union League Club – NYC

Mr. Emalfarb will be available during the event for one-one-one meetings. Interested investors and industry partners may request a one-on-one meeting at [email protected] or contact Dyadic at (561) 743-8333.

About
Dyadic International

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Myceliophthora thermophila, named C1. The C1 microorganism, which enables the development and large scale manufacture of low-cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs (such as virus like particles (VLPs) and antigens), monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Recently, Dyadic has also begun exploring the use of its C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of Adeno-associated viral vectors (AAV), certain metabolites and other biologic products. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to create synergy by leveraging Dyadic’s technologies in development and manufacture of biopharmaceuticals. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and as a result improve access and cost to patients and the healthcare system, and most importantly, save lives.

Please visit Dyadic’s website at http://www.dyadic.com/ for additional information, including details regarding Dyadic’s plans for its biopharmaceutical business.

Safe
Harbor Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including those regarding Dyadic’s expectations, intentions, strategies and beliefs pertaining to future events or future financial performance. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors, including those described in Dyadic’s most recent filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. Dyadic assumes no obligation to update publicly any such forward-looking statements, whether as a result of new information, future events or otherwise. For a more complete description of the risks that could cause our actual results to differ from our current expectations, please see the section entitled “Risk Factors” in Dyadic’s annual reports on Form 10-K and quarterly reports on Form 10-Q filed with the SEC, as such factors may be updated from time to time in Dyadic’s periodic filings with the SEC, which are accessible on the SEC’s website atwww.dyadic.com.

Contact:

Dyadic International, Inc.
Ping W. Rawson
Chief Financial Officer
Phone: (561) 743-8333
Email: 
[email protected]

SOURCE: Dyadic International, Inc.


View source version on accesswire.com: 
https://www.accesswire.com/557923/Dyadic-to-Present-at-Janney-Healthcare-Conference

News Provided by ACCESSWIRE via QuoteMedia

Everything from A-to-Z: There are Consumer Cyclical Stocks for Everyone

Everything from A-to-Z: There are Consumer Cyclical Stocks for Everyone

The consumer cyclical sector includes a broad range of companies all the way from automotive to travel and leisure. Their stocks’ performance relies on the business cycle and the current economic state. When the economy is strong and consumers have a larger disposable income, spending in these industries increases and the performance reflects in the stock price. On the other hand, when the economy contracts and consumers have less disposable income, spending on entertainment and luxuries shrinks. Remember also that company performance depends on the niche that it fills; smallcap companies in this sector are affected by the same economic conditions and business cycles as largecaps. Regarding investing, many internal and external factors must be considered when selecting the right companies for your portfolio.